LOXO-292 showed robust and durable activity in previously treated patients with RET-altered tumors, including NSCLC, regardless of prior therapy.
Pembrolizumab addition to platinum-based chemotherapy significantly improved PFS and OS as first-line therapy for metastatic squamous NSCLC, with benefit demonstrated regardless of PD-L1 expression level.
In this phase II trial, consolidation pembrolizumab improved time to metastatic disease or death and PFS compared with historical outcomes.
In preliminary results, first-line combination chemoimmunotherapy with durvalumab achieved an ORR of 58% and 6-month PFS of 65% in advanced MPM.
Pembrolizumab showed promising antitumor activity in patients with SCLC, particularly those with PD-L1–positive tumors.
For patients with < 1% PD-L1 tumor expression, PFS benefit with first-line nivolumab combinations was limited to those who also had high tumor mutational burden.
Addition of atezolizumab to carboplatin/paclitaxel + bevacizumab significantly prolonged PFS and OS when given as first-line therapy in advanced nonsquamous NSCLC.
In patients with advanced EGFR mutation–positive NSCLC, first-line dacomitinib significantly improved OS vs gefitinib by 7.3 months with a 24% reduced risk of death.
In this planned interim analysis, first-line pembrolizumab significantly improved OS vs CT in patients with NSCLC and PD-L1 TPS ≥ 1% with a 19% reduced risk of death.
Sequencing of plasma cfDNA noninvasively identified patients with lung cancer regardless of stage, method of diagnosis, histology, or smoking status.
Addition of atezolizumab to carboplatin/nab-paclitaxel extended PFS compared with chemotherapy alone in patients with previously untreated metastatic squamous NSCLC.